Beam Therapeutics
Stock Forecast, Prediction & Price Target
Beam Therapeutics (BEAM) stock Price Target by analysts
$55
Potential upside: 235.36%
Beam Therapeutics price prediction
What is Beam Therapeutics stock analysts` prediction?
Beam Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Beam Therapeutics in the last 3 months, the avarage price target is $55, with a high forecast of $NaN. The average price target represents a 235.36% change from the last price of $16.4.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Beam Therapeutics stock Price Target by analysts
Full breakdown of analysts given Beam Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Rick Bienkowski Leerink Partners | 0% 0/1 | 10 months ago | $39 137.80% upside | $24.34 | StreetInsider | Previous targets (0) |
Kostas Biliouris BMO Capital | 0% 0/2 | 10 months ago | $57 247.56% upside | $24.34 | StreetInsider | Previous targets (1) |
Benjamin Burnett Stifel Nicolaus | 0% 0/1 | 12 months ago | $69 320.73% upside | $23.34 | StreetInsider | Previous targets (0) |
Unknown Cantor Fitzgerald | N/A | over 2 years ago | $62 278.04% upside | $43.45 | Benzinga | N/A |
Kostas Biliouris BMO Capital | 0% 0/2 | over 2 years ago | $66 302.43% upside | $41.59 | StreetInsider | Previous targets (1) |
Unknown Citigroup | N/A | over 2 years ago | $62 278.04% upside | $48.19 | Benzinga | N/A |
Unknown Credit Suisse | N/A | over 3 years ago | $62 278.04% upside | $39.83 | Benzinga | N/A |
Beam Therapeutics Financial Estimates
Beam Therapeutics Revenue Estimates
Beam Therapeutics EBITDA Estimates
Beam Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $51.84M N/A | $60.92M 17.50% | $377.70M 520.00% | Avg: $52.03M Low: $17.63M High: $70.55M avg. -86.22% | Avg: $59.40M Low: $17.87M High: $86.15M avg. 14.15% | Avg: $81.89M Low: $24.64M High: $118.76M avg. 37.85% | Avg: $216.85M Low: $65.25M High: $314.50M avg. 164.81% |
Net Income
% change YoY
| $-341.36M N/A | $-263.58M 22.78% | $-132.52M 49.72% | Avg: $-432.10M Low: $-435.90M High: $-254.60M avg. -226.05% | Avg: $-454.43M Low: $-481.42M High: $-212.93M avg. -5.16% | Avg: $-362.56M Low: $-574.79M High: $-33.06M avg. 20.21% | Avg: $-261.45M Low: $-414.51M High: $-23.84M avg. 27.88% |
EBITDA
% change YoY
| $-414.30M N/A | $-401.48M 3.09% | $-156.47M 61.02% | Avg: $-45.94M Low: $-62.29M High: $-15.57M avg. 70.63% | Avg: $-52.44M Low: $-76.06M High: $-15.78M avg. -14.15% | Avg: $-72.29M Low: $-104.85M High: $-21.75M avg. -37.85% | Avg: $-191.45M Low: $-277.66M High: $-57.61M avg. -164.81% |
EPS
% change YoY
| -$5.31 N/A | -$3.76 29.19% | -$1.72 54.25% | Avg: -$4.72 Low: -$5.65 High: -$3.3 avg. -174.55% | Avg: -$4.71 Low: -$6.24 High: -$2.76 avg. 0.21% | Avg: -$4.7 Low: -$7.45 High: -$0.43 avg. 0.27% | Avg: -$3.39 Low: -$5.37 High: -$0.31 avg. 27.88% |
Operating Expenses
% change YoY
| $444.30M N/A | $399.39M -10.10% | $554.19M 38.75% | Avg: $24.75B Low: $8.39B High: $33.56B avg. 4366.06% | Avg: $28.25B Low: $8.50B High: $40.97B avg. 14.15% | Avg: $38.95B Low: $11.72B High: $56.49B avg. 37.85% | Avg: $103.14B Low: $31.03B High: $149.59B avg. 164.81% |
FAQ
What is Beam Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -45.77% in 2025-2028.
We have gathered data from 10 analysts. Their low estimate is -435.90M, average is -432.10M and high is -254.60M.
What is Beam Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 32.64% in 2025-2028.
We have gathered data from 10 analysts. Their low revenue estimate is $17.63M, average is $52.03M and high is $70.55M.
What is Beam Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -36.54% in 2025-2028.
We have gathered data from 10 analysts. Their low earnings per share estimate is -$5.65, average is -$4.72 and high is $-3.3.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Beam Therapeutics stock. The most successful analyst is Rick Bienkowski.